KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $80.1 million.

  • Pacira BioSciences' Accumulated Expenses rose 4.28% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 4.28%. This contributed to the annual value of $80.1 million for FY2024, which is 24.72% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Accumulated Expenses is $80.1 million, which was up 24.72% from $64.2 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Accumulated Expenses registered a high of $127.6 million during FY2021, and its lowest value of $64.2 million during FY2023.
  • Over the past 3 years, Pacira BioSciences' median Accumulated Expenses value was $80.1 million (recorded in 2024), while the average stood at $78.1 million.
  • Per our database at Business Quant, Pacira BioSciences' Accumulated Expenses spiked by 79.72% in 2021 and then declined by 29.61% in 2022.
  • Pacira BioSciences' Accumulated Expenses (Yearly) stood at $71.0 million in 2020, then soared by 79.72% to $127.6 million in 2021, then decreased by 29.61% to $89.8 million in 2022, then declined by 28.45% to $64.2 million in 2023, then climbed by 24.72% to $80.1 million in 2024.